• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Oxaliplatin “Ebewe”
    / Novartis


    Active Ingredient
    Oxaliplatin 50, 100, 150 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 x 50 mg

    partial basket chart 82015 15362

    Vial

    1 x 100 mg

    partial basket chart 82017 15363

    Vial

    1 x 150 mg

    partial basket chart 82018 15364

    Related information


    Dosage

    See prescribing information fol full details.


    Indications

    In combination with 5-fluorouracil and folinic acid (FA), is indicated for: Adjuvant treatment of stage III (Duke C) colon cancer after complete resection of the primary tumor; treatment of advanced colorectal cancer.


    Contra-Indications

    Hypersensitivity to oxaliplatin or to any of the constituents. Myelosuppression prior to starting first course, as evidenced by baseline. Pregnancy & lactation. See prescribing information fol full details.


    Special Precautions

    Should only be used in specialised departments of oncology and administered under the supervision of an experienced oncologist.
    See prescribing information fol full details.


    Side Effects

    Myelosuppression (neutropenia, thrombocytopenia, anemia.
    See prescribing information fol full details.


    Drug interactions

    See prescribing information fol full details.


    Manufacturer
    Ebewe Pharma
    Licence holder
    CLOSE